How accelerated atherosclerosis in SLE has changed our management of the disorder

Abstract

Basic science insights along with the assessment of risk factors so clearly documented by the Canadian and Hopkins cohorts in earlier papers of this special issue have clearly led to a change in the way rheumatologists manage SLE. This review will highlight specific ways it should alter our day to day treatment of lupus patients.

Keywords

coronary artery disease (CAD)systemic lupus erythematosus (SLE)corticosteroids (CS)

Get full access to this article

View all access options for this article.

References

Ward MM , Pyun E , Studenski S . Causes of death in systemic lupus erythematosus. Long-term follow-up of an inception cohort . Arthritis Rheum 1995; 38 (10): 1492–1499 .

Jacobsen S , Petersen J , Ullman S et al. A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factos of prognostic value . Clin Rheumatol 1998; 17 (6): 478–484 .

Koh ET , Seow A , Leong KH , Chng HH . SLE mortality in an oriental population . Lupus 1997; 6 (1): 27–31 .

Petri M , Perez-Gutthann S , Spence D , Hochberg MC . Risk factors for coronary artery disease in patients with systemic lupus erythematosus . Am J Med 1992; 93 (5): 513–519 .

Kannel WB , Castelle WP , Gordon T , McNamara PM . Serum lipoproteins and the risk of coronary artery disease . Ann Intern Med 1971; 74: 1–12 .

Roussouw JE . The effects of lowering serum cholesterol on coronary heart disease risk . Med Clin North Am 1994; 78: 181–195 .

MacGregor AJ , Dhillon VB , Binder A et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus . Ann Rheum Dis 1992; 51 (2): 152–155 .

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . The Expert Panel. 1988; 148 (1): 36–69 .

Scandinavian Simvastatin Survival Study Group . Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) . Lancet 1994; 344: 1383–1389 .

10.

Manninen V , Elo MO , Frick KH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study . JAMA 1988; 260: 641–651 .

11.

Lipid Research Clinics Program . The Lipid Research Clinics Coronary Primary Prevention trials. 1. Reduction in incidence of coronary artery disease . JAMA 1984; 251: 351–364 .

12.

Coronary Drug Project Research Group . Clofibrate and Niacin in coronary artery disease . JAMA 1975; 231: 360–381 .

13.

Wallace DJ , Podell T , Weiner J et al. Lupus nephritis: experience with 230 patients in a private practice from 1950-1980 . Am J Med 1982; 72: 209–220 .

14.

Wallace DJ , Metzger AL , Stecher VJ et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids . Am J Med 1990; 89 (3): 322–326 .

15.

Rahman P , Gladman DD , Urowitz MB et al. The cholesterol lowering effect of antimalarial drugs is enhanced in patients with lupus taking corticosteroid drugs . J Rheumatol 1999; 26 (2): 325–330 .

16.

Tsakonas E , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus 1998; 7 (2): 80–85 .

17.

van Vollenhoven RF , Engleman EG , McGuire JL . Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial . Arthritis Rheum 1995; 38: 1826–1831 .

18.

Tam LS , Li EK , Leung CB et al. Long-term treatement of lupus nephritis with cyclosporin A . QJM 1998; 91 (8): 573–580 .

19.

Dooley MA , Cosio FG , Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations . J Am Soc Nephrol 1999; 10 (4): 833–839 .

20.

Rahman P , Humphrey-Murto S , Gladman DD , Urowitz MB . Efficacy and tolerability of methotrexate in antimalarial resistant lupus arthritis . J Rheumatol 1998; 25 (2): 243–246 .

21.

Boumpas DT , Austin HA III , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340 (8822): 741–745 .

22.

Petri M , Roubenoff R , Dallal GE et al. Plama homocysteine as a risk facto for atherothrombotic events in systemic lupus erythematosus . Lancet 1996; 348 (9035): 1120–1124 .

23.

Fijnheer R , Roest M , Haas FJ et al. Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study . J Rheumatol 1998; 25 (9): 1737–1742 .

24.

Lahita RG , Rivkin E , Cavanagh I , Romano P . Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus . Arthritis Rheum 1993; 36 (11): 1566–1574 .

25.

Greisman SG , Thayaparan RS , Godwin TA , Lockshin MD . Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardioilipin antibody . Arch Intern Med 1991; 151: 389–392 .

26.

Cowchock SG , Reece EA , Balaban D et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment . Am J Obstet Gynecol 1992; 166: 1318–1323 .

27.

Vaarala O , Puurunen M , Likka M et al. Affinity purified cardiolipin binding antibodies show heterogeneity in their binding to oxidized low density lipoprotein . Clin Exp Immunol 1996; 104: 269–274 .

28.

Horkko S , Miller E , Dudi E et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids . J Clin Invest 1996; 98: 815–825 .

29.

Hasunma Y , Matsuura E , Makita Z et al. Involvement of beta-2 glycoprotein 1 and anticardiolipin antibodies in oxidatively modified low density lipoprotein uptake by macrophages . Clin Exp Immunol 1997; 107: 569–573 .

30.

George J , Afek A , Gilburd B et al. Atherosclerosis in LDL receptor knockout mice is accelerated by immunization with anticardiolipin antibodies . Lupus 1997; 6: 723–729 .

31.

Bruce IN , Gladman DD , Urowitz MB . Detection and modification of risk factors for coronary artery disease in patients with systemic lupus erythematosus: a quality improvement study . Clin Exp Rheumatol 1998; 16 (4): 435–440 .

32.

Meacham LR , Abdul-Latif H , Sullivan K , Culler FL . Predictors of change in insulin sensitivity during glucocorticoid treatment . Horm Metab Res 1997; 29 (4): 172–175 .

33.

Ginzler EM , Felson DT , Anthony JM , Anderson JJ . Hypertension increases the risk of renal deterioration in systemic lupus erythematosus . J Rheumatol 1993; 20 (10): 1694–1700 .

34.

Naiker IP , Chrystal V , Randeree IGH , Seedat YK . The significance of arterial hypertension at the onset of clinical lupus nephritis . Postgrad Med J 1997; 73: 230–233 .

35.

Petri M . Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus . Lupus 1998; 7: (S1) 61-61 .

36.

Brown K , Petri M , Goldman D . Cutaneous manifestations of SLE: Associations with other manifestations of SLE and with smoking . Arthritis Rheum 1996; 39: S291-S291 .

37.

Rahman P , Goldman DD , Urowitz MB . Smoking interferes with efficacy of antimalarial therapy in cutaneous lupus . J Rheumatol 1998; 25: 1716–1719 .

38.

Ramsey-Goldman R , Chang RW , Dunlop D et al. Exercise in patients with systemic lupus erythematosus (SLE): Pilot study . Arthritis Rheum 1995; 38: S242-S242 .

39.

Sturfelt G , Eskilsson J , Nived O et al. Cardiovascular disease in systemic lupus erythematosus. A study of 75 patients from a defined population . Medicine (Baltimore) 1992; 71 (4): 216–223 .